Iovance: Decoding Cancer's Challenger & TIL Therapy's Future

2 Views
Published
Company: IOVANCE BIOTHERAPEUTICS, INC.
Filing Type: 10-K
Date: Thu, 27 Feb 2025 17:15:54 EST

Filing Details:
• CIK: 0001425205
• Accession Number: 0001558370-25-001834
• File Number: 001-36860

Checkout the filing on the official SEC website: https://www.sec.gov/Archives/edgar/data/1425205/000155837025001834/0001558370-25-001834-index.htm
Category
Oncology
Be the first to comment